Page 1 | Search Results | Blood | American Society of Hematology

1-5 of 5

Sort by

Sort Order Select

Journal Articles

The Role Of NF-κB In The Activation Of Human iNKT Cells In Sickle Cell Disease Patients and In Vitro

Jennifer C. Yu, MD, Gene Lin, MD, PhD, Ruey Ken, PhD, Joshua J. Field, MD, MS, Joel Linden, PhD

Blood (2013) 122 (21): 2291.

https://doi.org/10.1182/blood.V122.21.2291.2291

Published: 2013

Journal Articles

Human Sickle Cell Disease Increases Numbers and Activation Of Peripheral Blood Myeloid Dendritic Cells, Monocytes, and Neutrophils

Gene Lin, MD, PhD, Jennifer C. Yu, MD, Joshua J. Field, MD, MS, David G. Nathan, MD, Joel Linden, PhD

Blood (2013) 122 (21): 1033.

https://doi.org/10.1182/blood.V122.21.1033.1033

Published: 2013

Journal Articles

NF-κB Activation Mediates Induction Of Anti-Inflammatory Adenosine A2A Receptors In iNKT Cells Of Sickle Cell Patients During Vaso-Occlusive Episodes and Upon Activation Of Cultured Human iNKT Cells

Joel Linden, PhD, Gene Lin, MD, PhD, Jennifer C. Yu, MD, Donna S. Neuberg, ScD, David G. Nathan, MD, Joshua J. Field, MD, MS

Blood (2013) 122 (21): 975.

https://doi.org/10.1182/blood.V122.21.975.975

Published: 2013

Journal Articles

Sickle cell vaso-occlusion causes activation of iNKT cells that is decreased by the adenosine A 2A receptor agonist regadenoson

Joshua J. Field, Gene Lin, Maureen M. Okam, Elaine Majerus, Jeffrey Keefer, Onyinye Onyekwere, Ainsley Ross, Federico Campigotto, Donna Neuberg, Joel Linden, David G. Nathan

Blood (2013) 121 (17): 3329–3334.

https://doi.org/10.1182/blood-2012-11-465963

Published: 2013

Includes: Supplemental data

Journal Articles

Regadenoson, An Adenosine 2A Receptor Agonist, Is Safe and Inhibits Invariant NKT Cells in Sickle Cell Disease

Joshua Field, MD, MS, Gene Lin, MD, PhD, Maureen Okam, MD, MPH, Elaine Majerus, MD, PhD, Onyinye Onyekwere, MD, MS, Ainsley Ross, BA, Donna Neuberg, ScD, Federico Campigotto, MS, David G. Nathan, MD, Joel Linden, PhD

Blood (2011) 118 (21): 849.

https://doi.org/10.1182/blood.V118.21.849.849

Published: 2011

NARROW

The Role Of NF-κB In The Activation Of Human iNKT Cells In Sickle Cell Disease Patients and In Vitro

Human Sickle Cell Disease Increases Numbers and Activation Of Peripheral Blood Myeloid Dendritic Cells, Monocytes, and Neutrophils

NF-κB Activation Mediates Induction Of Anti-Inflammatory Adenosine A2A Receptors In iNKT Cells Of Sickle Cell Patients During Vaso-Occlusive Episodes and Upon Activation Of Cultured Human iNKT Cells

Sickle cell vaso-occlusion causes activation of iNKT cells that is decreased by the adenosine A 2A receptor agonist regadenoson

Regadenoson, An Adenosine 2A Receptor Agonist, Is Safe and Inhibits Invariant NKT Cells in Sickle Cell Disease

Email alerts

ASH Publications

American Society of Hematology

The Role Of NF-κB In The Activation Of Human iNKT Cells In Sickle Cell Disease Patients and In Vitro

Human Sickle Cell Disease Increases Numbers and Activation Of Peripheral Blood Myeloid Dendritic Cells, Monocytes, and Neutrophils

NF-κB Activation Mediates Induction Of Anti-Inflammatory Adenosine A2A Receptors In iNKT Cells Of Sickle Cell Patients During Vaso-Occlusive Episodes and Upon Activation Of Cultured Human iNKT Cells

Sickle cell vaso-occlusion causes activation of iNKT cells that is decreased by the adenosine A 2A receptor agonist regadenoson

Regadenoson, An Adenosine 2A Receptor Agonist, Is Safe and Inhibits Invariant NKT Cells in Sickle Cell Disease

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only